Ipsen SA's appetite for business development has not been sated and just over a month after agreeing to acquire Epizyme, Inc., the French firm has furthered its cancer pipeline by getting access to compounds from Marengo Therapeutics and AGV Discovery.
First up, Ipsen has agreed to pay $45m upfront to help advance two immuno-oncology candidates generated by Marengo’s Selective T...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
